UBS Group’s Orexigen Therapeutics, Inc. OREX Stock Holding History

UBS Group’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-170	Closed	-$3K	–	8885
2015 Q4	$3K	Hold	170	–	–	﹤0.01%	7968
2015 Q3	$4K	Hold	170	–	–	﹤0.01%	7911
2015 Q2	$8K	Hold	170	–	–	﹤0.01%	7661
2015 Q1	$13K	Sell	170 -280	-62%	-$17.4K	﹤0.01%	7468
2014 Q4	$27K	Buy	+450	New	+$22.6K	﹤0.01%	7259

Other funds holding OREX

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

UBS Group's OREX Position: Q2 2018 in Review

UBS Group sold out of Orexigen Therapeutics, Inc. (OREX) in Q2 2018, closing a stake of 11,155 shares — an estimated $3K sold.

UBS Group first reported a position in OREX in Q4 2014 and held it in 14 quarters. The position peaked at $98K in Q1 2015. 4 funds tracked by Wall St. Rank hold OREX as of Q2 2018.

UBS Group reported no remaining Orexigen Therapeutics, Inc. position as of Q2 2018 after selling out during the quarter.
UBS Group sold 11,155 Orexigen Therapeutics, Inc. shares in Q2 2018, an estimated $3K.
UBS Group first reported a position in Orexigen Therapeutics, Inc. in Q4 2014 and held it in 14 quarters.
UBS Group's Orexigen Therapeutics, Inc. position peaked at $98K in Q1 2015.
4 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q2 2018.

Based on UBS Group's 13F filing for Q2 2018, filed 14 Aug 2018.